Compare Amgen, Inc. (AMGN) vs Honest Company Inc (HNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Honest Company Inc — how do they compare? Amgen, Inc. trades at $363.26 (market cap $196.12B), while Honest Company Inc trades at $4.01 (market cap $441.42M). The key difference: Amgen, Inc. is far larger — about 444.3× Honest Company Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| AMGN | HNST | |
|---|---|---|
Market Cap | $196.12B | $441.42M |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $4.95 |
52-Week Low | $271.18 | $2.10 |
Enterprise Value | $241.41B | $362.81M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HNST trades at $4.01, up 1.26% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Cash flow from operations improved to $15.12M in 2025, though revenue declined slightly to $371.32M. Analyst sentiment is mixed with 30% buy ratings.
The outlook remains cautious due to persistent unprofitability and competitive pressures, though cost controls and gross margin expansion offer some upside. Key risks include execution challenges in shifting to retail channels and reliance on wipes & personal care for growth. Investors should weigh improving cash flows against weak bottom-line trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
